ASO Author Reflections: Total Parietal Peritonectomy During Interval Cytoreductive Surgery for Advanced Ovarian Cancer—Proof-of-Principle and Analysis of Morbidity-Reference-Cited by-同舟云学术

ASO Author Reflections: Total Parietal Peritonectomy During Interval Cytoreductive Surgery for Advanced Ovarian Cancer—Proof-of-Principle and Analysis of Morbidity

Published:2020-07-27 Issue:S3 Volume:27 Page:861-862
ISSN:1068-9265
Container-title:Annals of Surgical Oncology
language:en
Short-container-title:Ann Surg Oncol

Author:

Bhatt Aditi^ORCID,Kammar Praveen,Mehta Sanket,Sinukumar Snita

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Surgery

Link

https://link.springer.com/content/pdf/10.1245/s10434-020-08940-6.pdf

Reference5 articles.

1. Hynninen J, Lavonius M, Oksa S, et al. Is perioperative visual estimation of intra- abdominal tumor spread reliable in ovarian cancer surgery after neoadjuvant chemotherapy? Gynecol Oncol. 2013;128:229–32.

2. Sinukumar S, Rajan F, Mehta S, Damodaran D, Zaveri S, Kammar P, et al. A comparison of outcomes following total and selective peritonectomy performed at the time of interval cytoreductive surgery for advanced serous epithelial ovarian, fallopian tube and primary peritoneal cancer: a study by INDEPSO. Eur J Surg Oncol. 2019. pii: S0748-7983(19)30304-X. https://doi.org/10.1016/j.ejso.2019.02.031.

3. Lim MC, Song YJ, Seo SS, Yoo CW, Kang S, Park SY. Residual cancer stem cells after interval cytoreductive surgery following neoadjuvant chemotherapy could result in poor treatment outcomes for ovarian cancer. Onkologie. 2010;33(6):324–30. https://doi.org/10.1159/000313823.

4. Bhatt A, Kammar P, Sinukumar S, Parikh L, Jumale N, Shaikh S, et al. Total parietal peritonectomy can be performed with acceptable morbidity in patients with advanced ovarian cancer following neoadjuvant chemotherapy: results from a prospective multi-centric study. Ann Surg Oncol. 2020. https://doi.org/10.1245/s10434-020-08918-4.

5. Di Giorgio A, De Iaco P, De Simone M, et al. Cytoreduction (peritonectomy procedures) combined with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in advanced ovarian cancer: retrospective Italian multi-center observational study of 511 cases. Ann Surg Oncol. 2017;24:914–22.

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Perioperative outcomes and platinum resistant recurrence in patients undergoing systematic, protocol-based, total parietal peritonectomy during interval cytoreductive surgery for advanced ovarian cancer: results of the TORPEDO study;Journal of Gynecologic Oncology;2024

2. Perioperative outcomes and platinum resistant recurrence in patients undergoing protocol based total parietal peritonectomy during interval cytoreductive surgery for advanced ovarian cancer- results of the TORPEDO study;2023-10-09

3. Platinum resistant recurrence and early recurrence in a multi-centre cohort of patients undergoing interval cytoreductive surgery for advanced epithelial ovarian cancer;Frontiers in Oncology;2022-09-02

4. Surgical and systemic therapies for addressing occult disease in advanced epithelial ovarian cancer;European Journal of Gynaecological Oncology;2022

5. Greater-omentum lesion-score (GOLS) as a predictor of residual disease in different regions of the peritoneal cavity in patients undergoing interval cytoreductive surgery for advanced ovarian cancer and its potential clinical utility;European Journal of Surgical Oncology;2021-11